- Home
- GILD vs PANW Comparison
GILD vs PANW Comparison
Compare GILD & PANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | PANW |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.6B | 143.7B |
| IPO Year | 1992 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GILD | PANW |
|---|---|---|
| Price | $119.14 | $187.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 40 |
| Target Price | $127.10 | ★ $223.18 |
| AVG Volume (30 Days) | ★ 7.0M | 6.5M |
| Earning Date | 10-30-2025 | 11-19-2025 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | ★ 6514.05 | N/A |
| EPS | ★ 6.42 | 1.58 |
| Revenue | ★ $29,087,000,000.00 | $9,556,500,000.00 |
| Revenue This Year | $3.63 | $16.46 |
| Revenue Next Year | $2.97 | $13.25 |
| P/E Ratio | ★ $18.75 | $121.32 |
| Revenue Growth | 2.79 | ★ 15.30 |
| 52 Week Low | $88.57 | $144.15 |
| 52 Week High | $128.70 | $223.61 |
Technical Indicators
Market Signals| Indicator | GILD | PANW |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 38.64 |
| Support Level | $118.78 | $188.50 |
| Resistance Level | $123.74 | $193.66 |
| Average True Range (ATR) | 2.64 | 4.39 |
| MACD | -0.74 | 0.13 |
| Stochastic Oscillator | 8.16 | 22.03 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.